The scale of the investigation is what sets it apart. The research team, led by Zihan Dong of Karolinska Institutet in Sweden together with an international consortium spanning more than thirty institutions, identified 1,929,027 adults who received a first recorded diagnosis of type 2 diabetes between 2010 and 2020. Of these, roughly 47 percent were male. Because the study drew on national health registries, insurance claims databases, and prescription records rather than self-report, the researchers could capture ADHD diagnoses and medication dispensations with a degree of completeness that smaller single-country studies cannot match. Each national dataset was analysed under a standardized analytical protocol before the results were combined, a design choice that minimizes the methodological heterogeneity that has plagued earlier cross-study comparisons.

The headline result is stark: adults with type 2 diabetes and co-occurring ADHD had a hazard ratio of 2.42 for all-cause mortality after their diabetes diagnosis, with a 95 percent confidence interval of 1.72 to 3.41. In practical terms, even after accounting for the uncertainty inherent in observational data, the death rate among these patients was more than double that of their diabetes-only counterparts. Crucially, the association held after the researchers adjusted for sex, age, calendar year at diabetes diagnosis, psychiatric history, use of other psychotropic medications, and use of cardiometabolic drugs—the standard arsenal of confounders that critics of pharmacoepidemiology studies typically raise. The consistency of the signal across seven healthcare systems with different diagnostic cultures, treatment guidelines, and record-keeping infrastructures strengthens the case that the finding reflects a genuine clinical phenomenon rather than an artifact of any single country’s data.

Perhaps more surprising is what the study did not find. ADHD was not consistently associated with major adverse cardiac events—a composite outcome encompassing acute myocardial infarction, stroke, and cardiovascular disease-related death. The pooled hazard ratio for MACE was 1.04, with a confidence interval of 0.81 to 1.35, meaning the data cannot distinguish the true effect from no effect at all. This dissociation between mortality and cardiac events is scientifically intriguing. It suggests that the excess deaths among diabetes patients with ADHD may not be driven primarily by the classical cardiovascular pathway that dominates outcomes research in type 2 diabetes. Alternative explanations could include non-cardiac causes of death, difficulties with diabetes self-management, higher rates of psychiatric comorbidity, medication non-adherence, or lifestyle factors that are harder to capture in registry data. The authors note that the mortality signal was robust while the cardiac one was not, a pattern that warrants deeper investigation into the specific causes of death in this population.

The study also examined a second, clinically urgent question: among adults who have both type 2 diabetes and ADHD, does taking ADHD medication change cardiovascular risk? Here the answer was conditional and age-dependent. Overall, ADHD medication use was not associated with elevated MACE risk across the full cohort. But when the researchers stratified by age at diabetes onset, a clear signal emerged: among patients diagnosed with type 2 diabetes before age 45—so-called early-onset type 2 diabetes—ADHD medication use was associated with a hazard ratio of 1.58 for major adverse cardiac events, with a confidence interval of 1.18 to 2.10. That interval excludes the null value, indicating a statistically reliable elevation in risk within this younger subgroup.

The age stratification matters because early-onset type 2 diabetes is itself an aggressive disease. Patients diagnosed in early adulthood accumulate longer lifetime exposure to hyperglycemia and typically face higher cumulative risks of retinopathy, nephropathy, and cardiovascular complications than those diagnosed later in life. Layering stimulant and non-stimulant ADHD medications onto an already vulnerable metabolic profile may compound that risk. Stimulant medications such as methylphenidate and amphetamine derivatives act on the sympathetic nervous system, raising heart rate and blood pressure—effects that are generally well tolerated in healthy adults but potentially consequential in patients with insulin resistance, dyslipidemia, and emerging vascular disease. The study’s time-varying exposure design, which allowed medication status to change over the follow-up period rather than being fixed at baseline, lends additional credibility to this subgroup finding.

Methodologically, the researchers employed cause-specific Cox proportional hazards models, the workhorse of survival analysis, to estimate hazard ratios with 95 percent confidence intervals for each country separately. These country-specific estimates were then pooled using random-effects meta-analysis, a technique that assumes the true effect may vary across populations and quantifies that variability rather than pretending it does not exist. Treating both ADHD status and medication use as time-varying exposures was a deliberate safeguard against immortal time bias, a subtle distortion that arises when researchers classify patients by a status they could only achieve after surviving a certain period. The adherence to the STROBE reporting guidelines for observational epidemiology further signals the team’s attention to transparency and reproducibility.

The study was supported by the European Union Horizon 2020 Research and Innovation Programme, along with national funders including the Australian National Health and Medical Research Council, and the funders had no role in the design, analysis, or publication decisions. The authors declared a range of competing interests typical of a large psychiatric-pharmacoepidemiology collaboration, including speaker fees and research funding from pharmaceutical companies for several senior investigators, all reported as outside the submitted work. The article is published open access under a Creative Commons Attribution license, and the team has shared supplementary materials detailing the country-specific analyses.

For clinicians, the message is twofold. First, a diagnosis of ADHD in an adult with type 2 diabetes should prompt intensified monitoring and integrated somatic-psychiatric care, because the co-occurrence marks a population at substantially elevated risk of dying. Adults with ADHD are, on average, diagnosed with type 2 diabetes at younger ages and may experience greater difficulty adhering to complex medication regimens, dietary recommendations, and glucose monitoring routines—mechanisms the study’s authors flag as plausible contributors to the mortality gap. Second, the decision to prescribe ADHD medication to a patient with early-onset type 2 diabetes deserves careful individualized consideration, weighing the demonstrated benefits of treatment on function and safety against a possible cardiovascular signal in this vulnerable group. The researchers emphasize that their findings suggest a potential need for integrated care models and careful medication stewardship, particularly for younger-onset diabetes, rather than any blanket restriction on ADHD treatment.

The broader significance of the work lies in its demonstration that psychiatric comorbidity is not a peripheral concern in metabolic disease. As ADHD diagnoses in adults continue to rise and as type 2 diabetes increasingly affects younger populations, the overlap between the two conditions will grow. Studies of this scale, harnessing the combined statistical power of seven national data systems, provide the evidentiary foundation that single-country analyses cannot. What remains to be established is the mechanism: whether the doubled mortality reflects biological interactions, behavioral pathways, healthcare access disparities, or some combination of all three. Answering that question will determine whether the intervention that matters most is cardiological, psychiatric, or structural—and for now, the study’s authors argue, the safest bet is closer collaboration between the specialists who treat the brain and those who treat the blood sugar.

Subject of Research: The association of ADHD and ADHD medication use with major adverse cardiac events and mortality in adults with type 2 diabetes

Article Title: Major adverse cardiac events and mortality associated with ADHD and its treatment in adults with type 2 diabetes: a multi-national cohort study

Article References: Dong, Z., Zhou, Y., Yao, H., Liu, S., Astrup, A., Engeland, A., Gao, L., Gillies, M. B., Lunde, A., Zhang-James, Y., Araki, M., Brikell, I., Butwicka, A., Dalsgaard, S., D’Onofrio, B. M., Faraone, S. V., Gudbjornsdottir, S., Haavik, J., Kuja-Halkola, R., … Du Rietz, E. (2026). Major adverse cardiac events and mortality associated with ADHD and its treatment in adults with type 2 diabetes: a multi-national cohort study. BMC Medicine, 24(1), Article 527. https://doi.org/10.1186/s12916-026-05246-4

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05246-4

Keywords: ADHD, type 2 diabetes, major adverse cardiac events, mortality, ADHD medication, cardiovascular risk, cohort study, pharmacoepidemiology, early-onset diabetes, multinational study, psychiatric comorbidity, BMC Medicine

The study, published in the European Journal of Nuclear Medicine and Molecular Imaging, was led by Rong Wang of Gansu Provincial Hospital in Lanzhou and Wei Dong of Beijing Anzhen Hospital, Capital Medical University. The researchers enrolled 174 patients who had undergone percutaneous coronary intervention, or PCI, the umbrella term for stenting and related catheter-based procedures. Crucially, every participant had angiographically confirmed complete revascularization, meaning their large epicardial arteries showed no significant residual blockages. In other words, by conventional measures, these hearts had been fixed. The question was whether a deeper look would reveal lingering trouble.

The deeper look came from a technology called dynamic SPECT, abbreviated D-SPECT, which uses fast cadmium-zinc-telluride detectors to track a radioactive tracer moving through the heart muscle in real time. Traditional perfusion scans capture a single static snapshot of blood distribution, revealing only whether some regions of the heart look dimmer than others. Dynamic imaging goes further: by measuring how quickly the tracer arrives and washes out, clinicians can calculate absolute blood flow in milliliters per gram per minute, both at rest and during pharmacological stress, when a drug dilates the vessels to simulate exercise. The ratio of stress flow to rest flow yields the myocardial flow reserve, or MFR — a numerical gauge of how much extra blood delivery the heart can summon when demand rises.

A healthy heart can multiply its resting blood flow several-fold under stress. When that reserve falls below 2.0, it signals that the coronary microvasculature — the dense network of arterioles and capillaries too small to appear on any angiogram — cannot dilate properly. The researchers defined coronary microvascular disease, or CMD, as a global or territorial MFR below this threshold in the absence of any epicardial stenosis greater than 50 percent. This definition matters because microvascular dysfunction is increasingly recognized as a disease entity in its own right, one that causes ischemia, drives symptoms, and worsens outcomes even when the conduit arteries are wide open. Prior work has linked it to adverse remodeling of the heart muscle, diastolic dysfunction, and elevated risk in patients with diabetes and prior infarction.

The results were striking. Over a median follow-up of 12 months, during which some patients were followed for as long as 21 months, 42 of the 174 patients — 24.1 percent — suffered a major adverse cardiac event. The composite endpoint was deliberately broad, encompassing all-cause death, myocardial infarction, unscheduled coronary revascularization, stroke, hospitalization for heart failure, and rehospitalization for angina. When the investigators split the cohort by microvascular status, the difference was unmistakable: patients with CMD experienced significantly higher event rates, a separation visible on survival curves with a log-rank statistic of 11.375 and a p-value of 0.001.

What makes the finding clinically persuasive is that it survived rigorous statistical scrutiny. The team applied multivariable Cox regression, adjusting for traditional cardiovascular risk factors and for abnormal findings on conventional myocardial perfusion imaging. Even after accounting for these established predictors, CMD remained an independent predictor of adverse outcomes, carrying a hazard ratio of 2.46 — meaning patients with impaired flow reserve faced roughly two and a half times the risk of a major event compared with those whose microvessels functioned normally. The 95 percent confidence interval ranged from 1.27 to 4.76, and the p-value of 0.007 indicated the association was unlikely to be chance. Notably, the association held consistently across all prespecified patient subgroups.

The study also delivered a technical refinement with practical implications. Rather than relying solely on a single global MFR value averaged over the whole left ventricle, the researchers analyzed regional MFR — flow reserve measured separately in the territories supplied by each of the major coronary arteries. Statistical reclassification analyses quantified how much this regional approach added. The net reclassification improvement, or NRI, was 0.524, and the integrated discrimination improvement, or IDI, was 0.036, both statistically significant. In plain terms, looking at the heart territory by territory reclassified a meaningful fraction of patients into more accurate risk categories and improved the model’s ability to distinguish those who would have events from those who would not. A globally normal flow reserve can mask a severely diseased single territory, and the regional analysis catches what the average conceals.

The implications extend beyond the cardiology ward. Coronary microvascular dysfunction has long been difficult to assess outside specialized centers, historically requiring invasive catheter-based measurements such as the index of microcirculatory resistance, which involves threading a pressure-temperature sensor wire into the coronary artery. Noninvasive quantification with dynamic CZT-based SPECT offers a way to screen patients after PCI without additional catheterization. If confirmed, the approach could change post-procedural care: patients flagged with low flow reserve might be candidates for intensified medical therapy targeting the microcirculation — including aggressive risk-factor control, antiplatelet and lipid-lowering regimens, and emerging microvascular-directed treatments — while those with robust reserves might be spared unnecessary interventions and anxiety.

The authors are careful to frame their conclusions appropriately. This was a pilot study, exploratory in design, with a relatively modest sample size and a median follow-up of only one year — short by the standards of cardiovascular outcomes research. The researchers themselves call for validation in larger multi-center studies with longer follow-up and direct comparisons against invasive reference measurements. The cohort was drawn from two Chinese hospitals, Gansu Provincial Hospital and Beijing Anzhen Hospital, and whether the findings generalize to other populations remains to be demonstrated. Ethical approval was obtained from both institutions, and the work was funded by the National Natural Science Foundation of China along with provincial and municipal research programs.

Even with those caveats, the study adds an important piece to one of cardiology’s most persistent puzzles: why symptoms and events persist after anatomically successful revascularization. It reinforces a conceptual shift that has been gathering momentum in the field — that the coronary circulation must be evaluated as a whole, from the epicardial conduits down to the microscopic vessels where oxygen actually exchanges with heart muscle. For the roughly one in four patients in this cohort destined for a major cardiac event despite complete stenting, a 20-minute dynamic nuclear scan may soon offer something that angiography never could: a genuine look at the plumbing that matters most, and a head start on preventing the next crisis before it strikes.

Subject of Research: D-SPECT-derived myocardial flow reserve for detecting coronary microvascular disease and predicting outcomes after complete revascularization

Article Title: Prognostic value of D-SPECT-derived myocardial flow reserve in detecting coronary microvascular disease and predicting outcomes after complete revascularization: a two-center pilot study

Article References: Wang, R., Bai, J., Xie, P., Wang, H., Wang, X., Gao, Z., Chen, Y., Mi, H., & Dong, W. (2026). Prognostic value of D-SPECT-derived myocardial flow reserve in detecting coronary microvascular disease and predicting outcomes after complete revascularization: a two-center pilot study. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08162-0

Image Credits: AI Generated

DOI: 10.1007/s00259-026-08162-0

Keywords: D-SPECT, myocardial flow reserve, coronary microvascular disease, percutaneous coronary intervention, major adverse cardiac events, nuclear cardiology, SPECT imaging, coronary microcirculation, prognosis, revascularization, cardiac imaging, Prognostic

The science behind the discovery rests on a nuclear medicine technique that has been refined over decades. Cardiac sympathetic nerve activity can be visualized using a radioactive tracer called iodine-123 metaiodobenzylguanidine, abbreviated 123I-MIBG. This molecule mimics norepinephrine, the chemical messenger that sympathetic nerve endings release to accelerate the heartbeat under stress. Because the tracer is taken up by the same transport machinery that recycles norepinephrine, images of its distribution reveal how well the cardiac sympathetic nervous system is functioning. Damaged or overactive nerve terminals handle the tracer abnormally, and one of the most informative measurements is the washout rate, which describes how quickly the tracer clears from the heart muscle between early and delayed scans. A high washout rate signals heightened sympathetic tone, a state long associated with arrhythmias, worsening heart function, and death in patients with heart disease.

What has remained unclear is whether the whole-heart measurement tells the whole story. Conventional practice relies on planar images, two-dimensional snapshots that average tracer behavior across the entire myocardium. The Japanese team, led by Takumi Kondo of Osaka General Medical Center, asked a more granular question: does the sympathetic activity measured specifically in the territory of the blocked artery, the culprit lesion, carry different prognostic weight than the activity in territories served by the other coronary arteries, the non-culprit regions? To find out, they prospectively enrolled 122 patients with STEMI and performed 123I-MIBG imaging with both planar and single photon emission computed tomography, or SPECT, which resolves the heart into three-dimensional regional detail.

The study design was rigorous and forward-looking. Every patient underwent imaging during the acute phase of their heart attack, and the investigators calculated a global washout rate from the planar images alongside separate average washout rates for the culprit and non-culprit territories on the SPECT images. The patients were then followed for an average of 4.2 years, with a standard deviation of 2.5 years, while the researchers tracked the occurrence of major adverse cardiac events, a composite endpoint that captures the outcomes patients and doctors fear most. During the follow-up period, 34 of the 122 patients experienced such an event, providing a substantial body of outcome data for statistical analysis.

The results delivered a genuine surprise. Both an abnormally high global washout rate on planar imaging and an increased washout rate in the non-culprit lesion were independently associated with major adverse cardiac events, even after the two measures were mutually adjusted against each other and after the analysis controlled for established clinical predictors including the widely used GRACE and TIMI risk scores. The washout rate in the culprit lesion, by contrast, showed no such independent association. In other words, sympathetic overactivity in the region of the heart that suffered the infarction did not add prognostic information, but sympathetic overactivity in the apparently healthy, remotely located myocardium did.

The explanation likely lies in the biology of the cardiac autonomic nervous system. Sympathetic nerves are distributed across the heart in a heterogeneous pattern, and injury or inflammation in one region can trigger widespread neural remodeling that extends well beyond the damaged zone. Previous histological and imaging work has documented that autonomic nerves course through the human heart in regionally variable ways, and animal studies have shown that sympathetic neuronal function and receptor populations recover on different schedules after ischemia and reperfusion. Remote sympathetic activation, sometimes amplified by interventions such as ischemic conditioning, has emerged as a therapeutic target in its own right. The new findings suggest that this remote neural disturbance is not a bystander phenomenon but an active driver of poor outcomes, plausibly by lowering the threshold for lethal ventricular arrhythmias and progressive ventricular dysfunction in tissue that remains structurally viable.

Perhaps the most clinically consequential result concerns patients who exhibit both abnormalities simultaneously. Those with both an abnormal global washout rate and an increased non-culprit washout rate faced a significantly higher risk of major adverse cardiac events than patients showing either abnormality alone, a difference that reached statistical significance with a p value of 0.025, and a dramatically higher risk than patients with neither abnormality, where the p value fell below 0.001. This dose-response-like layering indicates that the regional SPECT measurement provides genuinely incremental information on top of the conventional planar assessment. A two-tier imaging strategy, in which planar screening is followed by regional tomographic analysis, could therefore identify a small subgroup of heart attack survivors whose risk is substantially underestimated by every current scoring system.

The implications reach beyond risk prediction into treatment selection. Patients flagged as high risk by this neural signature might be candidates for more aggressive therapy, closer surveillance, earlier decisions about implantable cardioverter-defibrillators, or enrollment in trials of neuromodulation strategies aimed at calming the overactive cardiac sympathetic system. The same research group has previously shown that remote ischemic perconditioning can suppress sympathetic activation after acute myocardial infarction, and that MIBG imaging can track the effects of drugs such as nicorandil on nerve function. A measurable, regional index of sympathetic overactivity gives such interventions a concrete target and a way to verify whether they are working, potentially transforming the tracer technique from a passive prognostic tool into an active guide for therapy.

Certain caveats deserve emphasis. The study involved 122 patients at a single center in Osaka, and the imaging was performed in the acute phase, so it remains to be seen whether the non-culprit washout rate retains its predictive power when measured later, or in more diverse populations and health care systems. SPECT regional analysis also demands more expertise and processing time than a simple planar washout calculation, and questions about standardization across different cameras and centers, which have been addressed for other MIBG parameters in multicenter calibration work, will need answers for regional indices as well. Nevertheless, the core message is difficult to dismiss: after a heart attack, the nerves in the parts of the heart that were spared may matter more than the nerves in the parts that were not. As nuclear cardiology moves toward ever finer characterization of the heart’s neuroanatomy, the non-culprit territory has moved from the periphery of the image to the center of prognostic attention, and clinicians assessing STEMI survivors may soon want to look not only at where the artery was blocked, but at what the rest of the heart’s nervous system is doing.

Subject of Research: Prognostic value of regional cardiac sympathetic nerve activity measured by 123I-MIBG imaging in STEMI patients

Article Title: Cardiac sympathetic nerve activity in the non-culprit lesion predicts poor prognosis in patients with STEMI

Article References: Kondo, T., Yamada, T., Asai, M., Morita, T., Kawasaki, M., Kikuchi, A., Kawai, T., Seo, M., Nakamura, J., Fujita, T., Kokubu, Y., Oyama, F., Obayashi, H., Kurihara, H., Noda, K., Nishikawa, N., Suganami, A., Takahashi, M., Sakata, Y., & Fukunami, M. (2026). Cardiac sympathetic nerve activity in the non-culprit lesion predicts poor prognosis in patients with STEMI. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08186-6

Image Credits: AI Generated

DOI: 10.1007/s00259-026-08186-6

Keywords: STEMI, cardiac sympathetic nerve activity, 123I-MIBG imaging, SPECT, washout rate, non-culprit lesion, major adverse cardiac events, prognosis, nuclear cardiology, GRACE risk score, TIMI risk score, myocardial infarction